New drug gemini tested for kidney disease safety

NCT ID NCT06863467

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested a single dose of the experimental drug Gemini in 40 adults with stage 3 or 4 chronic kidney disease. The main goal was to check safety and side effects compared to a placebo. Researchers also measured how the drug moves through the body and its effect on inflammation and kidney function markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Gemini (a phosphorylated hexaacylated disaccharide)
What this could lead to
If successful, this could point toward a new way to reduce inflammation and slow kidney damage in chronic kidney disease.
What could go wrong
This is a very early, small study focused on safety, not effectiveness. It may not show any benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • California Institute of Renal Research

    Chula Vista, California, 91911, United States

  • California Institute of Renal Research

    La Mesa, California, 92942, United States

  • Clinical Advance Center, PLLC

    San Antonio, Texas, 78212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.